Search results
Showing 31 to 45 of 131 results for multiple sclerosis
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Awaiting development [GID-TA11721] Expected publication date: TBC
Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?
Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if...
people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...
with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...
people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis
Register an interest in this interventional procedure NICE has been notified about the above procedure and considered it part of the In...
methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...
Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a...